ABSTRACT
The available therapeutic strategies to manage allergic diseases consist of attempts either to desensitize the atopic individual to a given allergen or to diminish the ongoing allergic reaction.Anti-IgE as a novel therapeutic alternative was based on the premise that a therapy interfering with the binding of IgE molecules to both highand low-affinity receptors should reduce the allergen-induced early and late asthmatic responses by preventing the release of mediators from mast cells. In addition, this should decrease the amplification of the inflammatory responses mediated by helper T-cells by preventing IgE-dependent allergen presentation.
